However, due to the immunosuppressive microenvironment of liver cancer, conventional immune checkpoint inhibitors, such as programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), have limited therapeutic effects for liver cancer [7]. This evidence concerns the gene CTLA4 and liver cancer.